GSTZ1 deficiency contributes to sorafenib resistance in HCC through activation of the NRF2/GPX4 axis; thus, blocking the NRF2/GPX4 axis may have a therapeutic benefit in HCC patients with GSTZ1 deficiency. Here, NFE2L2 is linked to hepatocellular carcinoma.